Peptide News Digest

#Q2-2026-Earnings

23 stories

Industry · View digest

Alnylam Pharmaceuticals (NASDAQ: ALNY) Q2 2026 Earnings Preview for Thursday July 30 Before Market Open With 8:30 AM ET Conference Call: Wall Street Consensus of $2.05 Earnings Per Share (+540.6% Year-Over-Year) on Revenue of $1.32 Billion (+70.4% Year-Over-Year) Reflects the Continued Ramp of Amvuttra (Vutrisiran) for Both Hereditary Transthyretin Amyloid Polyneuropathy and Cardiomyopathy After the Q1 2026 Amvuttra Revenue of $889.9 Million (+187% YoY); Analyst Focus Includes ALN-6222 Obesity siRNA Phase 1 Program (NCT07624071) and the ALN-2232 Phase 1 Readout Expected in the Second Half of 2026

Alnylam Pharmaceuticals (NASDAQ: ALNY) reports Q2 2026 earnings Thursday July 30, 2026 before market open with an 8:30 AM ET conference call. Wall Street consensus estimates: EPS of $2.05 (+540.6% year-over-year) and revenue of $1.32 billion (+70.4% year-over-year), reflecting the continued commercial ramp of Amvuttra (vutrisiran) across both hereditary transthyretin amyloid polyneuropathy (hATTR-PN) and hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) after the Q1 2026 Amvuttra revenue of $889.9 million (+187% YoY). Analyst focus areas beyond the base-business ramp include: the ALN-6222 first-in-human Phase 1 obesity siRNA program (NCT07624071) that opened enrollment in July 2026 as a randomized double-blind placebo-controlled single-ascending-dose study of an undisclosed-target subcutaneous siRNA in adults with BMI 30-40 kg/m²; the ALN-2232 Phase 1 obesity program (Alnylam's second obesity-track siRNA) with Phase 1 readout expected in the second half of 2026; the Alnylam-PeptiDream peptide-siRNA conjugate extrahepatic delivery platform milestone announced December 2025; and the broader Alnylam 2030 strategy launch positioning beyond the Amvuttra franchise.

Industry · View digest

Kiniksa Pharmaceuticals (NASDAQ: KNSA) Reports Q2 2026 Financial Results and Recent Portfolio Execution on Tuesday July 28, 2026 With ARCALYST (Rilonacept) IL-1α and IL-1β Cytokine Trap Fusion Protein Net Product Revenue of $243.6 Million (+55% Year-Over-Year) for the Approved Recurrent Pericarditis Indication and Positive Phase 2 Data From the KPL-387 Program Showing Rapid and Sustained Reductions in Pain and Inflammation at the 300 mg Once-Monthly Subcutaneous Injection Dose; Kiniksa Hosted an 8:30 AM Eastern Time Conference Call to Discuss Q2 Financial Performance and Portfolio Pipeline Advancement

Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported Q2 2026 financial results Tuesday July 28, 2026 with ARCALYST (rilonacept, an IL-1α and IL-1β cytokine trap fusion protein) net product revenue of $243.6 million, +55% year-over-year growth. ARCALYST is FDA-approved for the reduction in risk of recurrence of pericarditis in patients 12 years of age and older, and represents Kiniksa's primary commercial franchise. The Q2 revenue trajectory reflects continued cardiovascular-specialist adoption of rilonacept as a maintenance therapy alternative to colchicine-plus-corticosteroid regimens in the recurrent pericarditis population. Kiniksa separately reported Phase 2 data from the KPL-387 program (an investigational IL-1 receptor antagonist monoclonal antibody) showing rapid and sustained reductions in pain and inflammation at the 300 mg subcutaneous injection administered once monthly. The company hosted a conference call and webcast at 8:30 AM Eastern Time Tuesday July 28 to discuss Q2 financial performance and portfolio pipeline advancement including KPL-387 next-step development, ARCALYST commercial expansion, and additional pipeline candidates. Kiniksa Pharmaceuticals is one of the peptide-adjacent biotech companies focused on IL-1 pathway inhibition through both antibody and fusion-protein modalities.

Clinical Trials · View digest

AstraZeneca (NYSE: AZN) Reports Q2 2026 Earnings Before Market Open Monday July 27, 2026 With Core EPS of $2.63 (+18% Constant Currency, Beating $2.48 Consensus) on Revenue of $15.38 Billion (+5%, In Line With $15.39 Billion Consensus) and Advances Elecoglipron (Oral Small-Molecule GLP-1 Receptor Agonist) Into the Full Phase 3 Program in Q2 Across the EMBOLD Obesity Trials, the ELUMINATE Type 2 Diabetes Trials (Including Monotherapy and Combination With Dapagliflozin), and Cardiovascular and Kidney Outcome Trials Positioning AstraZeneca to Challenge Novo Nordisk and Eli Lilly in the Oral GLP-1 Market Alongside the Positive Q2 Update on Tozorakimab (Peak Sales Now Projected Above $5 Billion, Raised From $3 Billion)

AstraZeneca (NYSE: AZN) reported Q2 2026 earnings before market open Monday July 27, 2026 with core earnings per share of $2.63 for the three months ended June 30 (+18% constant currency), beating consensus of $2.48. Revenue of $15.38 billion was in line with consensus of $15.39 billion (+5%). Analyst focus on the earnings call centered on the pipeline update: elecoglipron, the oral small-molecule GLP-1 receptor agonist AstraZeneca in-licensed and advanced through Phase 2 VISTA and SOLSTICE (positive data at ADA 2026 Scientific Sessions in June), has moved into a full Phase 3 program in Q2 2026. The Phase 3 program includes the EMBOLD trials in adults with obesity or overweight (with and without type 2 diabetes), the ELUMINATE trials in adults with type 2 diabetes (as monotherapy and in combination with dapagliflozin), and long-term cardiovascular and kidney outcome trials. AstraZeneca is now the third major sponsor competing with Novo Nordisk and Eli Lilly for the oral GLP-1 market alongside oral semaglutide/Ozempic and orforglipron (Foundayo, FDA-approved April 2026). AstraZeneca separately revised the peak sales projection for tozorakimab (experimental respiratory treatment) to above $5 billion from the previous $3 billion estimate. AZN shares rose approximately 1.7% in London Monday morning trading.

Clinical Trials · View digest

Alnylam Pharmaceuticals (NASDAQ: ALNY) Q2 2026 Earnings Preview for Thursday July 30, 2026 Before Market Open; Analyst Focus Areas Include the New ALN-6222 Investigational Subcutaneous siRNA Obesity Phase 1 Trial (NCT07624071, First-in-Human Single-Ascending-Dose Design Enrolling 88 Adults With BMI 30-40 kg/m² Through December 2027 at Mount Royal, Canada), the ALN-2232 Phase 1 Weight-Management Program (Phase 1 Readout Expected Second Half of 2026), the Alnylam-PeptiDream Peptide-siRNA Conjugate Extrahepatic Delivery Platform Milestone Announced December 2025, and the Broader Alnylam 2030 Strategy Launch Positioning Beyond the Amvuttra (Vutrisiran) Transthyretin Amyloidosis Franchise

Alnylam Pharmaceuticals (NASDAQ: ALNY) reports Q2 2026 earnings Thursday July 30, 2026 before market open. Analyst focus areas include the new ALN-6222 investigational subcutaneous siRNA obesity Phase 1 trial (NCT07624071, first-in-human single-ascending-dose randomized double-blind placebo-controlled design enrolling approximately 88 adults with BMI 30 to less than 40 kg/m² and HbA1c below 6.5% at a single site in Mount Royal, Canada through December 2027; molecular target of ALN-6222 has not been publicly disclosed). Also under focus: the Phase 1 ALN-2232 program (Alnylam's second obesity-track siRNA, with a Phase 1 readout expected in the second half of 2026), the Alnylam-PeptiDream peptide-siRNA conjugate extrahepatic delivery platform milestone announced December 2025 (demonstrating peptide-ligand-mediated targeted siRNA delivery to specific extrahepatic tissues), and the broader Alnylam 2030 strategy launch positioning beyond the Amvuttra (vutrisiran) transthyretin amyloidosis franchise. Alnylam's obesity pipeline is programmed against inhibin subunit beta E (INHBE) in liver and activin receptor type 1C (ACVR1C) in adipose tissue, both nucleic-acid modality targets that are distinct from GLP-1 agonism.

Industry · View digest

Q2 2026 Earnings Season for the Peptide-and-Obesity Big Three Opens Next Week With Merck Reporting Tuesday August 4, Eli Lilly Wednesday August 5, and Novo Nordisk Thursday August 6: Analyst Focus Areas Include Merck's LIPFENDRA (Enlicitide) FDA Approval Milestone One Week Old at Report Time, Eli Lilly's Foundayo (Orforglipron) First-Quarter-Out US Retail Sales, Zepbound Growth Versus the Wegovy Pill Franchise, and Novo Nordisk's Response to Analyst Concerns About 2027 Wegovy List Price Reset to $675 That Would Represent a 50% Cut From the Current Level

Q2 2026 earnings season for the peptide-and-obesity big three opens next week. Merck reports Tuesday August 4 at 9:00 AM ET with the LIPFENDRA (enlicitide) FDA approval milestone (July 16) roughly one week old at report time; analyst focus areas include the pricing strategy at $10.50 per tablet ($315 per 30-day supply), the pharmacy-benefit distribution model, and initial payer coverage momentum. Eli Lilly reports Wednesday August 5 before market open; analyst focus areas include Foundayo (orforglipron) first-quarter-out US retail sales (Q1 sales were not yet in the books at the last report), Mounjaro and Zepbound growth versus the Wegovy pill franchise, and TRIUMPH-2 and TRIUMPH-3 readouts for retatrutide expected later in 2026. Novo Nordisk reports Thursday August 6; analyst focus areas include the Wegovy pill uptake beyond the 3 million-prescription milestone documented at ADA 2026 (June), the impact of Novo's price cuts in China and India, the Vivani implant partnership announced July 7, and the response to analyst concerns about the January 2027 Wegovy list price reset to $675 (a 50% cut from current levels). The three earnings prints together are expected to frame the second-half 2026 obesity market trajectory and the competitive positioning of the incretin, amylin, and macrocyclic peptide franchises against each other.